TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00904670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quillivant Oral Suspension XR
Description: Oral Suspension 25mg/5mL; 20-60 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
Study: NCT00271856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: 8 week MBSR course

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV-education and self-management workshop
Description: 8-week group covering a variety of educational topics about managing HIV infection.
Study: NCT04880746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAC
Description: Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine combined with BEAC
Description: Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
Study: NCT00323960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 MPDN pulse + PDN
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 MPDN pulse + PDN + CSA
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 MPDN pulse + PDN + MTX
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
Study: NCT01599312

Intervention type: DEVICE
Group type: OTHER
Intervention: Forces exerted on teeth during intubation
Description: Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.

Intervention type: DEVICE
Group type: OTHER
Intervention: Forces exerted on teeth during intubation
Description: Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.

Intervention type: DEVICE
Group type: OTHER
Intervention: Forces exerted on teeth during intubation
Description: Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.

Intervention type: DEVICE
Group type: OTHER
Intervention: Forces exerted on teeth during intubation
Description: Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
Study: NCT03319459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor inhibitor antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2/neu receptor inhibitor
Study: NCT03456349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: HTL0018318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: HTL0018318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0018318
Description: HTL0018318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00435227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: A single IM dose of 30 mg/kg will be administered on Day 0 of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
Study: NCT05268692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS
Description: drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnP
Description: drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
Study: NCT00261378

Intervention type: DEVICE
Group type: OTHER
Intervention: DC Bead with Doxorubicin
Study: NCT04249791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of the uterus from live donor.
Description: Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
Study: NCT01432665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT02044367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Pellets (multiple dose of dabigatran)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Granules resolved in reconstitution solution (multiple dose of dabigatran)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Hard capsule (multiple dose of dabigatran)
Study: NCT01852500

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
Study: NCT04384653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection Solution for subcutaneous administration (80 mg)
Description: Furosemide Injection Solution for subcutaneous administration (80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection Solution for subcutaneous administration (80 mg)
Description: Furosemide Injection Solution for subcutaneous administration (80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection, USP
Description: Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection, USP
Description: Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medfusion 3500 (v6) precision infusion pump
Description: Furosemide Injection Solution for subcutaneous administration (80 mg)
Study: NCT01108003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mango Juice
Description: given orally
Study: NCT05047458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.
Study: NCT00268723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol tartrate HFA MDI
Description: levalbuterol MDI 90 mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI QID
Study: NCT03812874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-9908 Injection
Description: Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTX-9908 Injection
Description: Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)
Study: NCT02250937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01872494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local
Description: This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous
Description: This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.33% ropivacaine 250ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
Study: NCT01902914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hearing Aids Evaluation
Description: Functional Gain Sound field Speech Audiometry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aids Evaluation
Description: Functional Gain Sound field Speech Audiometry
Study: NCT04357158

Intervention type: DEVICE
Group type: OTHER
Intervention: AeonoseTM
Description: All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with \>2 weeks in between).
Study: NCT01086163

Intervention type: DRUG
Intervention: Omacor, omega-3 fatty acids in CAD patients
Description: Omacor 1g versus 2g daily versus placebo
Study: NCT03363529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic light
Description: Dynamic lighting is light that changes in intensity and spectral distribution during the day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Standard lighting is non-dynamical light corresponding to standard hospital lighting.
Study: NCT02746926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Study: NCT03595969

Intervention type: DIAGNOSTIC_TEST
Intervention: Relative copy number of mitochondrial DNA
Description: Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Relative copy number of mitochondrial DNA
Description: Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
Study: NCT04384653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medfusion 3500 (v6) precision infusion pump
Description: Furosemide Injection Solution for subcutaneous administration (80 mg)
Study: NCT04129359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilieTrivsel
Description: FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced care as usual
Description: Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enhanced care as usual
Description: Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
Study: NCT01894594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)
Study: NCT03052010

Intervention type: OTHER
Group type: OTHER
Intervention: Integrated PrEP as a bridge to ART HIV-1 prevention strategy
Description: The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services

Intervention type: DRUG
Group type: OTHER
Intervention: PrEP
Description: A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.

Intervention type: DRUG
Group type: OTHER
Intervention: ART
Description: ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
Study: NCT04206982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Destruction of Marshall bundles
Description: Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary veins isolation
Description: Achievement of a wide disconnection of the right and left pulmonary veins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary veins isolation
Description: Achievement of a wide disconnection of the right and left pulmonary veins.
Study: NCT03500822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metronome-paced tachypnea
Description: three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expiratory-stenosis breathing
Description: three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm